左西孟旦联合芪苈强心胶囊对顽固性心力衰竭的疗效分析  

Efficacy Analysis of Zuoximengdan Combined with Qiliqiangxin Capsules on Refractory Heart Failure

作　　者：徐健[1] 周雪[2] 赵纯[2] 李秀玲[1] XU Jian;ZHOU Xue;ZHAO Chun;LI Xiuling(Department of Cardiology,Jiangsu Fengxian People's Hospital,Xuzhou,Jiangsu Province,221700 China;Obstetrics and Gynecology Hospital of Nanjing Medical University,Nanjing,Jiangsu Province,210001 China)

机构地区：[1]江苏丰县人民医院心内科,江苏徐州221700 [2]南京医科大学附属妇产医院,江苏南京210001

出　　处：《中外医疗》2021年第32期95-97,101,共4页China & Foreign Medical Treatment

基　　金：2019年国家自然科学基金项目(81971386)。

摘　　要：目的分析左西孟且联合芪苈强心胶囊治疗顽固性心力衰竭的疗效。方法方便选取该院心血管内科收治的164例顽固性心力衰竭患者为研究对象,通过随机数表法将患者分为观察组和对照组,每组82例。观察组患者静脉滴注左西孟旦结合口服芪苈强心胶囊治疗,对照组静脉滴注左西孟旦。对比两组患者治疗前后的相关指标,记录治疗过程中出现的不良反应。结果治疗前,观察组和对照组的患者左心射血分数、N末端B型利钠肽原(NT-proBNP)对比,差异无统计学意义(P>0.05);治疗后,观察组患者的左心射血分数高于对照组,NT-proBNP低于对照组,差异有统计学意义(P<0.05)。治疗前,观察组和对照组患者血脂情况差异无统计学意义(P>0.05),治疗后,观察组血脂情况明显优于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率为95.12%(78/82),高于对照组76.82%(63/82),差异有统计学意义(χ^(2)=3.997,P<0.05)。结论在心力衰竭常规治疗方案的基础上予以静滴左西孟旦结合口服芪苈强心胶囊的治疗方法能有效改善顽固性心力衰竭患者的临床症状,具有较高的临床应用价值。Objective To analyze the efficacy of Lerosimerdan combined with Qiliqiangxin Capsule in the treatment of refractory heart failure.Methods 164 patients with intractable heart failure in the Department of Cardiology of the hospital were conveniently selected as the research objects.The patients were divided into observation group and control group by random number table method,with 82 cases in each group.Patients in the observation group received intravenous infusion of Levosimendan combined with oral Qiliqiangxin Capsules,while the control group received intravenous infusion of Levosimendan.Compared the relevant indicators of the two groups of patients before and after treatment,and record the adverse reactions that occurred during the treatment.Results Before treatment,the left ventricular ejection fraction and Nterminal pro-B-type natriuretic peptide(NT-proBNP)of the observation group and the control group were compared,and the difference was not statistically significant(P>0.05);after treatment,the observation group of the left ventricular ejection fraction was higher than that of the control group,NF-proBNP was lower than that in the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in blood lipids between the observation group and the control group(P>0.05).After treatment,the blood lipids of the observation group were significantly better than those of the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 95.12%(78/82),which was higher than 76.82%(63/82)in the control group,and the difference was statistically significant(χ^(2)=3.997,P<0.05).Conclusion The treatment of intravenous infusion of Levosimendan combined with oral Qiliqiangxin Capsule on the basis of the conventional treatment plan of heart failure can effectively improve the clinical symptoms of patients with refractory heart failure,and has high clinical application value.

关 键 词：左西孟旦 芪苈强心胶囊 顽固性心力衰竭 

分 类 号：R541[医药卫生—心血管疾病]